SPP1 and B-cell non-Hodgkin lymphoma: In addition, we detected SPP1 overexpression in 1/11 (9.1%) DLBCL patients (Figure 1A), and in 1/22 (4.5%) MCL patients (Figure S1), showing that SPP1 upregulation plays a role in subsets of selected B-cell lymphomas.